Weeks 56: Noticeable body definition, better muscle recovery, and visible lean mass development
For a good summary of the program eligibility requirements and benefits, see the chart below from The Medicare Rights Center : The Bridge Program will give access to the weight-reduction benefits of a GLP-1 to a Medicare recipient who is not currently on a GLP-1 and who qualifies because of a physician diagnosis of a BMI of at least 30 and certain accompanying health conditions, or a BMI of at least 27 with such medical conditions as pre-diabetes, prior heart attack, or peripheral artery disease
However, several considerations should be noted: Delayed gastric emptying : Saxenda significantly slows gastric emptying, which may affect the absorption of some oral medicines
For type 2 diabetes, NICE recommends GLP-1 receptor agonists when triple oral therapy is ineffective and BMI is 35 kg/m or higher (with lower thresholds for certain ethnic groups)
Enough with the science trivia
Romiplostim, as a peptibody, exhibits inherent advantages over the peptide IEGPTLRQWLAARA, notably in the pharmacokinetic properties (plasma half-life) and significant improvement in efficacy